Exos Asset Management’s Amedisys AMED Stock Holding History

Exos Asset Management’s Portfolio AMED Stock Details AMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-112	Closed	-$27K	–	471
2021 Q2	$27K	Buy	+112	New	+$29.4K	0.01%	652

Other funds holding AMED

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Exos Asset Management's AMED Position: Q3 2021 in Review

Exos Asset Management sold out of Amedisys (AMED) in Q3 2021, closing a stake of 112 shares — an estimated $27K sold.

Exos Asset Management first reported a position in AMED in Q2 2021 and held it in 1 quarter. The position peaked at $27K in Q2 2021. 351 funds tracked by Wall St. Rank hold AMED as of Q3 2021.

Exos Asset Management reported no remaining Amedisys position as of Q3 2021 after selling out during the quarter.
Exos Asset Management sold 112 Amedisys shares in Q3 2021, an estimated $27K.
Exos Asset Management first reported a position in Amedisys in Q2 2021 and held it in 1 quarter.
Exos Asset Management's Amedisys position peaked at $27K in Q2 2021.
351 funds tracked by Wall St. Rank held Amedisys as of Q3 2021.

Based on Exos Asset Management's 13F filing for Q3 2021, filed 25 Oct 2021.